INKON Life Technology Gestione

Gestione criteri di controllo 3/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Wen Peng

Amministratore delegato

CN¥1.8m

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	3.3yrs
Proprietà del CEO	n/a
Durata media del management	2.6yrs
Durata media del Consiglio di amministrazione	4.2yrs

Aggiornamenti recenti sulla gestione

Recent updates

AMMINISTRATORE DELEGATO

Wen Peng (56 yo)

3.3yrs

Mandato

CN¥1,778,900

Compensazione

Mr. Wen Peng has been General Manager of INKON Life Technology Co., Ltd. since August 25, 2021 and has been its Non-Independent Director since September 14, 2020. Mr. Peng served as the Deputy General Mana...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Wen Peng	GM & Director	3.3yrs	CN¥1.78m	Nessun dato
Lan Jiang	Financial Director	1.2yrs	CN¥202.10k	Nessun dato
Zelin Liu	Board Secretary	2yrs	CN¥506.20k	Nessun dato
Hongbo Li	Deputy General Manager	4.6yrs	CN¥1.05m	Nessun dato
Jinchen Xie	Accounting Supervisor	no data	Nessun dato	Nessun dato

2.6yrs

Durata media

48yo

Età media

Gestione esperta: Il team dirigenziale di 300143 è considerato esperto (durata media dell'incarico 2.6 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Wen Peng	GM & Director	4.2yrs	CN¥1.78m	Nessun dato
Lixia Tan	Chairman	5.5yrs	Nessun dato	Nessun dato
Xudong Shen	Non-Independent Director	5.5yrs	CN¥1.26m	Nessun dato
Mianshun Pan	Non-Independent Director	4.2yrs	CN¥457.60k	Nessun dato
Wenwen Gong	Chairman of the Supervisory Board	4.2yrs	Nessun dato	Nessun dato
Xudong Wang	Employee Representative Supervisor	5yrs	Nessun dato	Nessun dato
Xiaoman Chen	Independent Director	1.2yrs	CN¥30.00k	Nessun dato
Yuan Du	Independent Director	1.2yrs	CN¥30.00k	Nessun dato
Feng Jiang	Independent Director	1.2yrs	CN¥30.00k	Nessun dato

4.2yrs

Durata media

54yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 300143 sono considerati esperti (durata media dell'incarico 4.2 anni).

INKON Life Technology Gestione

Gestione criteri di controllo 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

INKON Life Technology Co., Ltd., Annual General Meeting, May 13, 2024

Inkon Life Technology Co., Ltd. Announces Directorate Appointments

High number of new directors

High number of new directors

High number of new and inexperienced directors

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.044 (vs CN¥0.039 in 3Q 2023)

Investor sentiment deteriorates as stock falls 18%

Investor sentiment improves as stock rises 32%

INKON Life Technology Co., Ltd. to Report Q3, 2024 Results on Oct 28, 2024

Now 23% undervalued

Investor sentiment improves as stock rises 19%

Second quarter 2024 earnings released: EPS: CN¥0.045 (vs CN¥0.057 in 2Q 2023)

INKON Life Technology Co., Ltd. to Report First Half, 2024 Results on Aug 23, 2024

INKON Life Technology Co., Ltd., Annual General Meeting, May 13, 2024

Full year 2023 earnings released: EPS: CN¥0.16 (vs CN¥1.01 loss in FY 2022)

INKON Life Technology Co., Ltd. to Report Q1, 2024 Results on Apr 26, 2024

INKON Life Technology Co., Ltd. (SZSE:300143) announces an Equity Buyback for CNY 80 million worth of its shares.

INKON Life Technology Co., Ltd. to Report Fiscal Year 2023 Results on Apr 22, 2024

Third quarter 2023 earnings released: EPS: CN¥0.039 (vs CN¥0.013 in 3Q 2022)

Now 21% undervalued after recent price drop

Inkon Life Technology Co., Ltd. Announces Directorate Appointments

INKON Life Technology Co., Ltd. to Report Q3, 2023 Results on Oct 27, 2023

Second quarter 2023 earnings released: EPS: CN¥0.057 (vs CN¥0.036 in 2Q 2022)

Full year 2022 earnings released: CN¥1.01 loss per share (vs CN¥0.57 loss in FY 2021)

High number of new directors

High number of new directors

Qingdao Haiyingkang Investment Co., Ltd. and INKON Life Technology Co., Ltd. (SZSE:300143) agreed to acquire Shenzhen Shengzhong Investment Enterprise (Limited Partnership) from a group of shareholders for CNY 87.7 million.

Third quarter 2022 earnings released: EPS: CN¥0.013 (vs CN¥0.12 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.036 (vs CN¥0.019 in 2Q 2021)

First quarter 2022 earnings released: EPS: CN¥0.038 (vs CN¥0.018 in 1Q 2021)

High number of new and inexperienced directors

Third quarter 2021 earnings released: EPS CN¥0.12 (vs CN¥0.026 in 3Q 2020)

Qingdao Yingkang Medical Investment Co., Ltd. acquired Hangzhou Yikang Traditional Chinese Medicine Tumor Hospital Co., Ltd. from INKON Life Technology Co., Ltd. (SZSE:300143) for CNY 1.3 million.

Second quarter 2021 earnings released: EPS CN¥0.019 (vs CN¥0.071 in 2Q 2020)

Investor sentiment deteriorated over the past week

First quarter 2021 earnings released: EPS CN¥0.018 (vs CN¥0.021 loss in 1Q 2020)

INKON Life Technology Co., Ltd. to Report Fiscal Year 2020 Results on Apr 23, 2021

New 90-day low: CN¥18.00

New 90-day low: CN¥20.30

New 90-day low: CN¥21.84

New 90-day low: CN¥22.19

Third quarter earnings released

First half earnings released

New 90-day high - CN¥25.25

INKON Life Technology Co., Ltd. to Report First Half, 2020 Results on Aug 28, 2020

INKON Life Technology Co., Ltd. announced that it has received CNY 732.939997 million in funding from Qingdao Yingkang Medical Investment Co., Ltd.

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media